Dave Ricks
Chair & CEO, Eli Lilly and Company. On 2 shows, 3 appearances. The Shows tab opens the full record on each.
executiveoperatorWikipedia ↗Instagram ↗
David A. Ricks has led Eli Lilly as CEO since 2017, overseeing its expansion into one of the world's most valuable pharmaceutical companies driven by blockbuster diabetes and obesity therapies like Mounjaro and Zepbound. Beyond Lilly, he serves on the board of directors of Adobe and the Purdue University Board of Trustees.
2shows
3appearances
122statements
59resolved
33supported
9contradicted
56%fully supported
1said about them ↓ Everything Dave Ricks said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Dave Ricks: CAR-T and gene therapies are difficult to scale to millions
“Those two techniques, CAR T and gene therapy, it's hard to think of like super scaled millions of people benefiting.”
Ricks: Leaders cannot change corporate culture, only amplify positive traits
“When you're running a big ship like this, probably changing the culture is like beyond your capability. But what you can do is like extend, turn up the things that are good and turn down the things That are less good.”
Ricks: Lilly will spend nearly 25% of revenue on R&D this year
“We'll spend almost 25% of sales this year.
John Collison: I liked your way of putting us that you spend more on medical R&D than Germany does.
Dave Ricks: Yes.
Dave Ricks: Yeah.
Dave Ricks: We're at the nation state level. It'll be, you know, fourteen billion …”
Ricks: Tirzepatide would be universally reimbursed if introduced in 1972
“If the first medicine we had to treat metabolic conditions was terzepatide in 1972, I have no doubt it would be reimbursed everywhere and broadly used in the system.”
Ricks: Eli Lilly is developing a one-time PCSK9 gene editing medicine
“We have a medicine development that will Knock down your LDL, if it's safe enough, and then one undone, PCSK nine edit in your liver, and presumably that will last the rest of your life, and your LDLs will be between 20 and 40 forever.”
Ricks: Around 80 GLP-1 drug candidates are in clinical pipelines globally
“We only have two right now, but there's probably 80 in clinical pipelines right now globally. We have 11 others, but there's probably 70 others not coming from Lilly.”
Ricks: The US and China hold 70% of global diagnostic capacity
“The US and China have something like 70% of all diagnostic capacity in the world.”
Ricks: Over half of approved drugs originate in biotech, but few finish
“While it's true that the origin of, I think it's a little more than half of medicines approved in the last 10 years have come from biotech, hardly any of those traveled all the way through biotech.”
Ricks: 80% of effective COVID treatments were produced in US
“Basically, 80% of the medicines and vaccines that worked were produced in the United States.”
Ricks: Marketing halves medical adoption time from 16 to eight years
“And there's been studies on this of medical inventions that are not promoted... It's about a sixteen-year path to full adoption. With the medicine promoted, it's half that. We have an internal goal to half that again, to get to four years, to full whatever it …”
Ricks: Extending human lifespans inherently increases total disease burden
“You know, there's no limit to human disease, and actually the longer we help people live, the more disease they'll be.”
Ricks: Lilly has small molecule and siRNA Lp(a) drugs in Phase 3
“Like we talked about LP a earlier. That was the case there. We discarded the antibody. There is one that's been developed. And we went after the small molecule and the siRNA. They're both in phase three.”
Eli Lilly spends $14.2 billion on R&D, equal to 25% of sales
“We spent 25% of sales on R&D. This year that'll be 14.2 billion dollars.”
Dave Ricks: Pharma companies lack enduring franchises due to patent cliffs
“In pharma, all our, we have no enduring franchise. Everything we make goes to zero because of the patent system.”
Dave Ricks predicts Mounjaro revenues will drop to zero in the 2030s
“So, in 20, 30 something, Manjaro will go to zero.”
Eli Lilly is building six US plants and announcing four more
“We're currently constructing six plants. We're going to announce four more in the next six months.”
Eli Lilly's Mounjaro demonstrated a 93% reduction in pre-diabetes conversion
“So we did that with Manjaro and showed a 93% reduction in conversion from pre-diabetes to diabetes.”
Dave Ricks: The US is the least metabolically healthy large country
“I think we are the least healthy metabolic big country, and probably the reason for that is the food we feed ourselves.”
Eli Lilly spends over half its consumer advertising budget outside TV
“By the way, more than half of our consumer spending to reach consumers is not on TV.”
Dave Ricks: Brain diseases account for 40% of global human suffering
“I think if you look at human suffering globally, 40% is brain diseases”
Eli Lilly and Genentech partnered to create the first-ever biotechnology product
“We had partnered with Genentech to do another first, which is create the first biotechnology product on planet earth, which was human insulin made in a bacterial cell.”
Science does not yet fully understand GLP-1's secondary metabolic effects
“What we don't even fully understand yet though, David, which is interesting is, is that there are primary effects of GLP-I. Certainly we can reproduce like in a test tube or a cell system, but then there's a whole myriad of other probably secondary effects bec…”
The other half of the tape: Dave Ricks's own voice is left out of every number here. Other people bring the name up 1 time in 1 episode across the shows. every mention, with the transcript →
Who brings them up most Chamath Palihapitiya 1
Every mention by year
tap a year for its mentions
All-In 1
2024 1 mention in 1 episode
One line per show, most statements first. The link opens Dave's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
| ALL-INLEDGER | Chair & CEO, Eli Lilly and Company | 2 | 71 | 55% 16/29 | full record on All-In → |
 CHEEKY PINTLEDGER | Chair & CEO, Eli Lilly and Company | 1 | 51 | 57% 17/30 | full record on Cheeky Pint → |